This article is more than 5 years old. Information may no longer be current.

Patent granted for method of use of Acucela’s Stargardt disease treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Patent and Trademark Office granted U.S. Patent No. 9,737,496 B2 to Acucela for method of use of its Stargardt disease treatment emixustat hydrochloride or a “broad number of related compounds,” according to a company press release.

Emixustat was granted orphan drug designation in January for the treatment of Stargardt disease, which affects fewer than 40,000 patients in the United States.

A phase 2a clinical study of the drug is currently underway in subjects with macular atrophy secondary to Stargardt disease.